[go: up one dir, main page]

HK1052464A1 - Ocular growth and nicotinic antagonists - Google Patents

Ocular growth and nicotinic antagonists Download PDF

Info

Publication number
HK1052464A1
HK1052464A1 HK03104752.7A HK03104752A HK1052464A1 HK 1052464 A1 HK1052464 A1 HK 1052464A1 HK 03104752 A HK03104752 A HK 03104752A HK 1052464 A1 HK1052464 A1 HK 1052464A1
Authority
HK
Hong Kong
Prior art keywords
ocular growth
nicotinic antagonists
ocular
growth
nicotinic
Prior art date
Application number
HK03104752.7A
Other languages
Chinese (zh)
Inventor
A. Stone Richard
M. Lindstrom Jon
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Publication of HK1052464A1 publication Critical patent/HK1052464A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention relates to a method comprising the step of ocular administration of therapeutically effective amounts of a nicotinic antagonist to control postnatal ocular growth or inhibit the development of myopia.
HK03104752.7A 2000-01-18 2001-01-18 Ocular growth and nicotinic antagonists HK1052464A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17687500P 2000-01-18 2000-01-18
US60/176,875 2000-01-18
PCT/US2001/001692 WO2001052832A1 (en) 2000-01-18 2001-01-18 Ocular growth and nicotinic antagonists

Publications (1)

Publication Number Publication Date
HK1052464A1 true HK1052464A1 (en) 2003-09-19

Family

ID=22646232

Family Applications (1)

Application Number Title Priority Date Filing Date
HK03104752.7A HK1052464A1 (en) 2000-01-18 2001-01-18 Ocular growth and nicotinic antagonists

Country Status (10)

Country Link
EP (1) EP1272170A1 (en)
JP (1) JP2003520228A (en)
KR (1) KR20020081260A (en)
CN (1) CN1418095A (en)
AU (1) AU775516B2 (en)
CA (1) CA2400803A1 (en)
HK (1) HK1052464A1 (en)
MX (1) MXPA02007039A (en)
RU (1) RU2002120485A (en)
WO (1) WO2001052832A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1978926A2 (en) * 2005-12-19 2008-10-15 Comentis, Inc. Topical mecamylamine formulations for ocular administration and uses thereof
FI20075498A7 (en) 2007-06-29 2008-12-30 Eero Castren Method for treating amblyopia with antidepressants
HUE069999T2 (en) 2017-03-06 2025-04-28 Tsubota Lab Inc Composition for use in the prevention or suppression of myopia
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
JP2022529353A (en) 2019-04-17 2022-06-21 コンパス パスファインダー リミテッド How to treat neurocognitive impairment, chronic pain and reduce inflammation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE203666T1 (en) * 1989-06-21 2001-08-15 Univ Pennsylvania USE OF A MUSCARINO ANTAGONIST FOR THE PRODUCTION OF A MEDICATION FOR THE TREATMENT AND REGULATION OF EYE DEVELOPMENT
US6710051B1 (en) * 1997-01-06 2004-03-23 Klaus Trier Aps Screening method

Also Published As

Publication number Publication date
AU775516B2 (en) 2004-08-05
KR20020081260A (en) 2002-10-26
CA2400803A1 (en) 2001-07-26
CN1418095A (en) 2003-05-14
JP2003520228A (en) 2003-07-02
AU3096901A (en) 2001-07-31
MXPA02007039A (en) 2003-09-25
EP1272170A1 (en) 2003-01-08
WO2001052832A1 (en) 2001-07-26
RU2002120485A (en) 2004-04-10

Similar Documents

Publication Publication Date Title
WO2002002525A3 (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
WO2001060347A3 (en) Method for treating ocular pain
WO2000057900A3 (en) Factor for regulation of neurite growth
MXPA02008402A (en) Derivatives of quinoline as alpha-2 antagonists.
DE60143197D1 (en) CRYSTALLINE FORM OF 5-CHLORO-3- (4-METHANESULFONYLPHENYL) -6'-METHYL-Ä2,3'Ü BIPYRIDINYL AND METHOD OF MANUFACTURING THEREOF
AU2001281078A1 (en) A mem gyroscope and a method of making same
WO2002051983A3 (en) Novel compounds and compositions as cathepsin inhibitors
AU2002241782A1 (en) Method of performing a lasik procedure and tonometer system for use therewith
WO1999006397A3 (en) Pyrrolidine-3-carboxylic acid derivatives and their use as endothelin antagonists
WO2001007049A3 (en) Ophthalmic composition comprising ketotifen
HK1040184A1 (en) Combination therapy for treating glaucoma
WO2001098270A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
HK1052464A1 (en) Ocular growth and nicotinic antagonists
WO2001058875A3 (en) Substituted 1,2,3,4- tetrahydroquinoline-2-carboxylic acid derivatives
EP0943311A3 (en) Method of inhibiting hair growth
AU2001256855A1 (en) Preparation for the prevention and treatment of ocular disorders
CA2301267A1 (en) Method of enhancing bioavailability of fexofenadine and its derivatives
WO2001098269A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
PT1248618E (en) 5-CHLORO-3- (4-METHANOSULPHONYLPHENYL) -6'-METHYL- [2,3 '] BIPYRIDINYL, POLYMORPHIC, AMORFAS AND HYDRATE
WO2005016327A3 (en) Treatment of sleep disorders with cholinesterase inhibitors
AU2001264522A1 (en) Methods and compositions for the prevention of myopia
WO2001087239A3 (en) Methods of affecting laminin 5 processing
AU2001289661A1 (en) Method of detecting compounds that control fungal diseases via effects on sporulation
AU2842501A (en) Method of controlling weeds
PL377052A1 (en) Crystalline fumarate salts of 1-azabicyclo[2.2.2]oct substituted furo[2,3-c]pyridinyl carboxamide and compositions and preparations thereof